Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 08, 2025 07:52 ET | Source: ZyVersa Therapeutics

ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis

ZyVersa provides regulatory and product support for Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a patient with ApoCII amyloidosis.
June 18, 2025 07:00 ET | Source: BPGbio

BPGbio Announces Presentation of Preliminary Clinical Data of Investigational BPM31510 for Primary CoQ10 Deficiency

BPM31510 provides encouraging evidence of the potential for transformative benefit for a disease with high unmet need, supporting further development.The Company plans to seek guidance in Q3 2025 from...
June 17, 2025 13:42 ET | Source: BioAegis Therapeutics

BioAegis Therapeutics Receives FDA Fast Track Designation for Lead Product, Recombinant Human Gelsolin, for the Treatment of Acute Respiratory Distress Syndrome (ARDS)

Fast Track status enables expedited regulatory review timelines and supports the development of recombinant human plasma gelsolin (rhu-pGSN), a novel immune modulator for inflammatory diseases. ...
January 22, 2025 16:05 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Discovery of New Immune Biomarkers in Multiple Sclerosis Patients Treated with Nasal Foralumab

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
August 13, 2024 08:00 ET | Source: Biomed Valley Discoveries, Inc.

Biomed Valley Discoveries Announces First Patient Dosed in Phase 2 Study of Its First-in-Class ERK 1/2 Inhibitor Ulixertinib in People with Histiocytosis

Biomed Valley Discoveries today announced that the first patient has been dosed in a Phase 2 study of ulixertinib for the treatment of histiocytosis.
October 09, 2018 18:00 ET | Source: Telix Pharmaceuticals Limited

GenesisCare and Telix Enter into Strategic Collaboration Agreement to Accelerate Patient Access to New Treatments

MELBOURNE, Australia and SYDNEY, Australia, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on...
January 06, 2016 02:00 ET | Source: Midatech Pharma PLC

Midatech Pharma PLC (“Midatech”, the “Company” or the “Group”) Pre-Close Trading Update

OXFORD, United Kingdom, Jan. 06, 2016 (GLOBE NEWSWIRE) -- Midatech Pharma (AIM:MTPH, Nasdaq: MTP), the international specialty pharmaceutical company focused on developing and commercialising...